KIR/HLA ligand matching and acute rejection after kidney transplantation.
- Author:
Li-xin YU
1
;
Fei XIAO
;
Lu-lu XIAO
;
Min LUO
;
Shao-jie FU
;
Yi-bin WANG
;
Yun MIAO
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Female; Graft Rejection; immunology; Graft Survival; immunology; HLA Antigens; immunology; Humans; Kidney Transplantation; adverse effects; immunology; Ligands; Male; Middle Aged; Receptors, KIR; immunology; Retrospective Studies; Signal Transduction; Young Adult
- From: Journal of Southern Medical University 2010;30(2):288-291
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of KIR/HLA ligand matching which mediates activated or inhibitory signal pathways on acute rejection (AR) after kidney transplantation.
METHODSHLA and KIR genotype assortments were analyzed in 53 donor/recipient pairs of kidney transplantation. The recipients were divided into AR group (GI, n=19) and stable renal function group (GII, n=34) based on the early graft function. The impact of donor HLA, recipient KIR and distinct KIR/HLA class I ligand combinations on acute rejection after kidney transplantation was studied.
RESULTSNo significant differences were found in donor HLA-C1/2, HLA-A3, HLA-A11, or HLA-Bw4 between GI and GII groups. The frequency for KIR2DL2/2DS2 and KIR genotype assortment (AA) of the recipients in GI group were significantly lower than that in GII group (26.3% vs 55.9%, P=0.038; 31.6% vs 67.6%, P=0.011). The incidence of AR was significantly lower in donor HLA-C1/1 than in non-C1/1 (31.6% vs 46.7%, P>0.05), and lower in recipient KIR genotype assortment (AA) than in non-AA (20.7% vs 52.2%, P=0.011). A significant higher number of matches for the KIR2DL2/ HLA-C1 and KIR2DL3/HLA-C1 were observed in GII group (P=0.030, P=0.028).
CONCLUSIONDistinct KIR/HLA class I ligand combinations between the donor and recipient (such as KIR2DL2/ HLA-C1 and KIR2DL3/HLA-C1) may reduce the incidence of AR. A good KIR/HLA class I ligand matching will benefit the survival of the renal allograft.